Form 4: Bio-Rad CEO Norman Schwartz Reports Stock Transactions

Bio-Rad Laboratories' Chairman and CEO, Norman Schwartz, reported the vesting of restricted stock units and related share transactions.

Summary

• Norman Schwartz, Chairman and CEO of Bio-Rad Laboratories, reported transactions involving the company's Class A common stock and restricted stock units.
• On September 5, 2025, 16,439 restricted stock units (RSUs) were acquired.
• On September 6, 2025, 3,455 shares of Class A common stock were acquired upon the vesting of RSUs.
• Concurrently, 1,528 shares of Class A common stock were disposed of at a price of $295.43, likely for tax withholding purposes.
• Following these transactions, direct beneficial ownership of Bio-Rad A Common Stock is 443,434 shares, and Bio-Rad B Common Stock is 361,466 shares.
• Indirect beneficial ownership includes 13,006 shares of Bio-Rad B Common Stock by spouse and 4,060,054 shares of Bio-Rad B Common Stock by Blue Raven Partners, L.P., with beneficial ownership disclaimed except for pecuniary interest.
• Remaining direct beneficial ownership of Restricted Stock Units is 10,367.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and the sale of shares for tax withholding. This is a standard occurrence and does not indicate significant positive or negative news for the company's operations or financial health. The acquisition of new RSUs is a positive for executive retention.

Positives

• Vesting of 3,455 restricted stock units indicates continued compensation and retention of a key executive.
• The acquisition of 16,439 new restricted stock units on September 5, 2025, demonstrates ongoing equity incentives for the Chairman & CEO.

Negatives

• Disposition of 1,528 shares of Class A common stock, although likely for tax purposes, reduces the direct shareholding of the CEO.

Future Outlook

The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant, indicating future equity compensation.

Industry Context

This filing is a standard insider transaction report and does not provide information relevant to broader industry trends or competitors. It reflects routine executive compensation and equity management.

Related Party Transactions

• Indirect beneficial ownership of 4,060,054 shares of Bio-Rad B Common Stock by Blue Raven Partners, L.P., where the reporting person is a limited and general partner. Beneficial ownership is disclaimed except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and compensation practices. The disposition of shares for tax purposes is a minor dilution event but expected.
• Employees: Reflects standard executive compensation practices, which can influence overall company compensation philosophy.

Next Steps

• Future vesting of the remaining 10,367 restricted stock units will occur over the next four years at 25% per year on the yearly anniversary date of the grant.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). It does not contain any information that would fundamentally alter the investment thesis for Bio-Rad Laboratories. Therefore, a 'hold' recommendation is appropriate as there's no new material information to warrant a change in existing positions based solely on this filing.

Keywords

Bio-Rad Laboratories, BIO, BIO.B, Norman Schwartz, Form 4, Insider Trading, Restricted Stock Units, RSU vesting, Stock acquisition, Stock disposition, CEO, Director, 10% Owner